''Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, today announced the release of a report by PlanClear which studied Positron's 2010 accomplishments and unique market position. The ...'

''Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City. The focus represents a growing interest and validation of how PEM can ...'

''According to research revealed at the Society of Nuclear Medicine's 57th Annual Meeting, a multi-tracer molecular imaging technique using positron emission tomography (PET) provides detailed information about the physiological processes of cancerous ...'

''Based on its recent analysis of the cardiac molecular imaging systems market, Frost & Sullivan recognizes Positron Corporation with the 2010 North American Award for New Product Innovation, for its pioneering cardiac positron emission tomography (PET) ...'

''Just as with computed tomography (CT) and magnetic resonance imaging (MRI), the growth rate among non-radiologists who own or lease positron emission tomography (PET) equipment is also on the rise, contributing significantly to the ongoing issues ...'

''Johns Hopkins Medicine has become the latest academic medical center to acquire the Naviscan Positron Emission Mammography (PEM) scanner. The device will be utilized by Richard Wahl, M.D., F.A.C.R, Professor of Radiology and Nuclear Medicine at the ...'

''The U.S. Food and Drug Administration (FDA) announced publication of a final regulation on current good manufacturing practices (cGMPs) for the production of positron emission tomography (PET) drugs, as well as a guidance document describing acceptable ...'

''A prototype breast imaging system combining positron emission tomography (PET) and magnetic resonance imaging (MRI) technologies could greatly improve breast cancer imaging capabilities, according to researchers at SNM's 56th Annual Meeting. Although ...'

''ScienceDaily (Jun. 10, 2008) ? Researchers at UCLA's Jonsson Comprehensive Cancer Center have modified a common chemotherapy drug to create a new probe for Positron Emission Tomography (PET), an advance that will allow them to model and measure the ...'

''FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) ...'